Tabuk Pharmaceuticals Partners with Prestige BioPharma for commercialization of Tuznue Trastuzumab Biosimilar in MENA
Tuznue™ is a mAb biosimilar to Roche's Herceptin® (trastuzumab), which is used to treat patients with HER2-overexpressing breast cancer and HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma
February 14, 2021